Spring Bank Pharmaceuticals, Inc.
113 Cedar Street
75 articles with Spring Bank Pharmaceuticals, Inc.
11/25/2019As usual, it was a busy week for clinical trial updates. Here’s a look.
Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285
The Phase 1 trial aims to evaluate safety, tolerability and initial anti-tumor activity of IV SB 11285 in patients with advanced solid tumors.
Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll, chief executive officer, will present at the following investor conferences:
Spring Bank Pharmaceuticals Reports Third Quarter 2019 Financial and Operational Results and Provides Corporate Update
Company to host conference call on Monday, November 11, 2019 at 4:30pm EST to discuss current HBV landscape and update on the company’s development programs
10/21/2019Last week was busy for clinical trial news. Here’s a look.
Spring Bank Announces Interim Top-Line Results from the First Cohort of the Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy® in Chronic Hepatitis B Patients
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), today announced interim top-line results at 12 weeks from the first cohort of the ongoing Phase 2 trial evaluating the safety, efficacy and pharmacodynamics of escalating doses (50mg, 200mg and 400mg) of the investigational compound inarigivir co-administered with Gilead Sciences’ Vemlidy® (tenofovir alafenamide 25mg) for the treatment of chronic hepatitis B virus (HBV) infection.
Spring Bank Announces FDA Acceptance of IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, announced that its Investigational New Drug (IND) application for a Phase 1 trial of SB 11285,
Spring Bank Announces Research Agreement with The National Institute of Allergy and Infectious Diseases to Evaluate HBV Antisense Oligonucleotide Compounds
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), today announced that it has entered into a research agreement with The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to evaluate Spring Bank’s hepatitis B virus (HBV) antisense oligonucleotide compounds.
Spring Bank to Present Pre-Clinical Data on Its Novel STING Antagonist Program at The Autoimmunity Conference
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), today announced that it will present for the first time pre-clinical data from its STimulator of INterferon Genes (STING) antagonist program at The Autoimmunity Conference organized by the Federation of American Societies for Experimental Biology (FASEB) in Pacific Grove, California, from July 7-12, 2019.
12/26/2018Companies closed out the year with a number of appointments and hires to strengthen their leadership teams, including changes at the FDA, Melinta, CLSA, Virion, and more.
Spring Bank Pharmaceuticals, Inc. today announced it will present inarigivir soproxil (inarigivir) data in both an oral and poster presentation at the American Association for the Study of Liver Disease (AASLD) Annual Meeting (The Liver Meeting®) being held on November 9-13 in San Francisco, CA.
Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2017 Results on Wednesday, February 21
The company will provide its 2018 development outlook at 8:30am Eastern Time on Wednesday, February 21, 2018.
Dr. Leach brings to the company over 13 years of experience in the biopharmaceutical industry.
Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase II ACHIEVE Trial
All patients in this cohort have transitioned to tenofovir disoproxil fumarate300mg daily for an additional 12 weeks.
Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial and Operational Results
Quarter highlighted by data presentations at two conferences and the initiation of research collaborations.
Spring Bank Pharmaceuticals Announces Additional Inarigivir (Formerly SB 9200) Results From the ACHIEVE Trial in HBV Patients at AASLD Conference
The Data Safety Monitoring Board approves proceeding with enrollment of third cohort (inarigivir 100mg) of the ACHIEVE trial.
Spring Bank Pharmaceuticals, Inc. Announces Presentation Of Positive Preclinical Data On SB 11285 At The 2017 AACR Conference On Tumor Immunology And Immunotherapy
Spring Bank Pharmaceuticals, Inc. To Present Additional Data From The First Cohort Of Its Ongoing SB 9200 ACHIEVE Clinical Trial At The 2017 International HBV Meeting In Washington D.C.
Spring Bank Pharmaceuticals, Inc. Provides Corporate Update And Reports Second Quarter 2017 Financial And Operational Results
Spring Bank Pharmaceuticals, Inc. Announces Collaboration With Gilead For Hepatitis B (HBV) Phase II Study Exploring Combination Treatment Of SB 9200 And Vemlidy